AI Financial Corporation
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsALT5 Sigma Corporation is a Nevada-based fintech and biotechnology company that also holds WLFI tokens under its Corporate and Other segment.
What they do
Through its Fintech segment, ALT5 Sigma provides blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets. Its Biotechnology segment, now presented as discontinued operations, is focused on developing non-addictive, non-sedative pain-relieving drugs. The Corporate and Other segment mainly consists of WLFI tokens acquired through a $1.5 billion registered direct offering and concurrent private placement in August 2025.
Revenue drivers
- Fintech segment — Generates revenue from blockchain-based services; recent quarterly revenues were $4.7M for the 13 weeks ended March 28, 2026.
- WLFI Treasury Strategy — Holds a substantial position in WLFI tokens; revenue impact not specified, but unrealized losses on cryptocurrency assets were $348.3M in the latest quarter.
- Biotechnology segment (discontinued operations) — Previously developed pain-relief drugs; now classified as discontinued operations, so no current revenue contribution from ongoing operations.
Recent performance
For the 13 weeks ended March 28, 2026, revenue was $4.7M, down from $4.8M in the prior-year quarter. Gross profit improved to $3.6M from $1.9M, but operating loss widened to $2.7M from $1.9M. The company recorded an unrealized loss of $348.3M on cryptocurrency assets, driving a significant net loss. Annual revenue for fiscal 2025 was $24.8M, with a net loss of $344.5M.
Strategy
Management has adopted a 'capital with a purpose' strategy, positioning the company as a significant institutional holder of WLFI tokens. The stated policy is a long-term 'HODL' approach, with future acquisitions funded through operating cash flows, structured debt, and selective capital raises. Sales of WLFI are restricted to liquidity requirements or material portfolio rebalancing events. The Biotech segment is intended to be decoupled via a subsidiary capitalization and financing.
Risks
- Cryptocurrency market volatility — The large unrealized loss of $348.3M in the latest quarter underscores exposure to volatile digital asset prices.
- Delisting risk — The company received a delisting notice or listing-rule failure on July 2, 2026, which could affect its Nasdaq listing.
- Funding and liquidity constraints — Cash and equivalents were only $10.5M as of March 28, 2026, while operating cash flow was negative $7.2M in fiscal 2025.
- Regulatory and compliance exposure — The company's WLFI holdings and digital asset operations may be subject to evolving regulatory scrutiny.
Outlook
Management has not provided specific forward guidance. The company expects to continue its WLFI Treasury Strategy and may raise capital selectively. The Biotech segment is planned to be separated into a standalone subsidiary. The ongoing delisting process and regulatory risks create uncertainty about future operations.